PRNewswire - 6 جون، 2026
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by …
خبر کامل دیکھیں
:strip_icc()/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2026/P/C/FB2EqPS7yjTSpgj5XhQg/05int-100-sds-a10-img01.jpg)
:strip_icc()/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2022/z/d/JOxSHhRhG6SBE5hBUWQw/plataforma-da-bp-no-golfo-do-mexico-divulgacao.jpg)
